GoodRx Holdings, Inc. $GDRX Shares Acquired by Pathway Capital Management LP

Pathway Capital Management LP boosted its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 69.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 986,158 shares of the company’s stock after purchasing an additional 402,721 shares during the period. GoodRx comprises about 20.5% of Pathway Capital Management LP’s holdings, making the stock its 3rd largest holding. Pathway Capital Management LP owned about 0.28% of GoodRx worth $4,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of GDRX. Lazard Asset Management LLC increased its holdings in shares of GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after buying an additional 5,201 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after purchasing an additional 7,580 shares in the last quarter. Cetera Investment Advisers acquired a new position in GoodRx in the 2nd quarter worth about $50,000. Walled Lake Planning & Wealth Management LLC bought a new position in GoodRx in the second quarter valued at about $55,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of GoodRx during the second quarter valued at about $58,000. Institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

GDRX has been the subject of several recent research reports. Jefferies Financial Group downgraded GoodRx to a “hold” rating in a research note on Thursday, January 22nd. Morgan Stanley decreased their price target on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Barclays assumed coverage on shares of GoodRx in a report on Monday, December 8th. They set an “underweight” rating and a $3.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Finally, UBS Group reaffirmed a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.73.

GoodRx Price Performance

GDRX stock opened at $2.28 on Tuesday. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The firm has a market cap of $773.91 million, a price-to-earnings ratio of 25.33, a PEG ratio of 0.86 and a beta of 1.45. The company’s fifty day simple moving average is $2.70 and its 200 day simple moving average is $3.55. GoodRx Holdings, Inc. has a 12-month low of $2.24 and a 12-month high of $5.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. During the same period last year, the business posted $0.08 earnings per share. The business’s revenue was up .4% on a year-over-year basis. On average, analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

GoodRx Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.